keyword
MENU ▼
Read by QxMD icon Read
search

american society of clinical oncology

keyword
https://www.readbyqxmd.com/read/29236202/sentinel-lymph-node-biopsy-and-management-of-regional-lymph-nodes-in-melanoma-american-society-of-clinical-oncology-and-society-of-surgical-oncology-clinical-practice-guideline-update
#1
Sandra L Wong, Mark B Faries, Erin B Kennedy, Sanjiv S Agarwala, Timothy J Akhurst, Charlotte Ariyan, Charles M Balch, Barry S Berman, Alistair Cochran, Keith A Delman, Mark Gorman, John M Kirkwood, Marc D Moncrieff, Jonathan S Zager, Gary H Lyman
PURPOSE: To update the American Society of Clinical Oncology (ASCO)-Society of Surgical Oncology (SSO) guideline for sentinel lymph node (SLN) biopsy in melanoma. METHODS: An ASCO-SSO panel was formed, and a systematic review of the literature was conducted regarding SLN biopsy and completion lymph node dissection (CLND) after a positive sentinel node in patients with melanoma. RESULTS: Nine new observational studies, two systematic reviews and an updated randomized controlled trial (RCT) of SLN biopsy, as well as two randomized controlled trials of CLND after positive SLN biopsy, were included...
December 13, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29232171/sentinel-lymph-node-biopsy-and-management-of-regional-lymph-nodes-in-melanoma-american-society-of-clinical-oncology-and-society-of-surgical-oncology-clinical-practice-guideline-update
#2
Sandra L Wong, Mark B Faries, Erin B Kennedy, Sanjiv S Agarwala, Timothy J Akhurst, Charlotte Ariyan, Charles M Balch, Barry S Berman, Alistair Cochran, Keith A Delman, Mark Gorman, John M Kirkwood, Marc D Moncrieff, Jonathan S Zager, Gary H Lyman
Purpose To update the American Society of Clinical Oncology (ASCO)-Society of Surgical Oncology (SSO) guideline for sentinel lymph node (SLN) biopsy in melanoma. Methods An ASCO-SSO panel was formed, and a systematic review of the literature was conducted regarding SLN biopsy and completion lymph node dissection (CLND) after a positive sentinel node in patients with melanoma. Results Nine new observational studies, two systematic reviews, and an updated randomized controlled trial of SLN biopsy, as well as two randomized controlled trials of CLND after positive SLN biopsy, were included...
December 12, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29232158/sentinel-lymph-node-biopsy-and-management-of-regional-lymph-nodes-in-melanoma-american-society-of-clinical-oncology-and-society-of-surgical-oncology-clinical-practice-guideline-update-summary
#3
Sandra L Wong, Erin B Kennedy, Gary H Lyman
No abstract text is available yet for this article.
December 12, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29227723/interventions-to-address-sexual-problems-in-people-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation-of-cancer-care-ontario-guideline
#4
Jeanne Carter, Christina Lacchetti, Barbara L Andersen, Debra L Barton, Sage Bolte, Shari Damast, Michael A Diefenbach, Katherine DuHamel, Judith Florendo, Patricia A Ganz, Shari Goldfarb, Sigrun Hallmeyer, David M Kushner, Julia H Rowland
Purpose The adaptation of the Cancer Care Ontario (CCO) guideline Interventions to Address Sexual Problems in People With Cancer provides recommendations to manage sexual function adverse effects that occur as a result of cancer diagnosis and/or treatment. Methods ASCO staff reviewed the guideline for developmental rigor and updated the literature search. An ASCO Expert Panel ( Table A1 ) was assembled to review the guideline content and recommendations. Results The ASCO Expert Panel determined that the recommendations from the 2016 CCO guideline are clear, thorough, and based upon the most relevant scientific evidence...
December 11, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29227716/interventions-to-address-sexual-problems-in-people-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-adaptation-summary
#5
Jeanne Carter, Christina Lacchetti, Julia H Rowland
No abstract text is available yet for this article.
December 11, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29223481/can-breast-cancer-patients-with-her2-dual-equivocal-tumours-be-managed-as-her2-negative-disease
#6
Yiwei Tong, Xiaosong Chen, Xiaochun Fei, Lin Lin, Jiayi Wu, Ou Huang, Jianrong He, Li Zhu, Weiguo Chen, Yafen Li, Kunwei Shen
BACKGROUND: Increasing human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC)/fluorescence in situ hybridisation (FISH) dual-equivocal breast tumours are reported after the 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline update. The aim of this study is to investigate the clinico-pathologic characteristics, treatment patterns and disease outcome of these patients with HER2 dual-equivocal tumours. PATIENTS AND METHODS: Patients with HER2 IHC 2+ and available FISH results were retrospectively analysed from the Comprehensive Breast Health Center, Shanghai Ruijin Hospital...
December 7, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29221705/female-fertility-preservation-in-the-pediatric-and-adolescent-cancer-patient-population
#7
REVIEW
Gabriela N Algarroba, Joseph S Sanfilippo, Hanna Valli-Pulaski
The 5-year survival rate for childhood cancer is over 80%, thereby increasing the number of young women facing infertility in the future because of the gonadotoxic effects of chemotherapy and radiation. The gonadotoxic effects of childhood cancer treatment vary by the radiation regimen and the chemotherapeutic drugs utilized. Although the American Society of Clinical Oncology guidelines recommend fertility preservation for all patients, there are several barriers and ethical considerations to fertility preservation in the pediatric and adolescent female population...
October 26, 2017: Best Practice & Research. Clinical Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/29207938/characterization-of-collaborative-practice-agreements-held-by-hematopoietic-stem-cell-transplant-pharmacists
#8
Amy Bryk, Susannah Koontz, JoAl Mayor, Jeffrey Betcher, Rebecca Tombleson, Ryan Bookout, Ila M Saunders
Background Current workforce shortages within the hematopoietic stem cell transplant field necessitate capitalizing on the role of oncology-trained pharmacists. Working within an agreed-upon protocol, pharmacists are able to expand patient care delivery through optimal medication therapy management. Methods An electronic survey was developed by the Advocacy & Policy Working Committee of the American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group and distributed to pharmacists involved in the care of hematopoietic stem cell transplant patients...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29203269/clinically-localized-prostate-cancer-aua-astro-suo-guideline-part-i
#9
Martin G Sanda, Jeffrey A Cadeddu, Erin Kirkby, Ronald C Chen, Tony Crispino, Joann Fontanarosa, Stephen J Freedland, Kirsten Greene, Laurence H Klotz, Danil V Makarov, Joel B Nelson, George Rodrigues, Howard M Sandler, Mary Ellen Taplin, Jonathan R Treadwell
PURPOSE: This guideline is structured to provide a clinical framework stratified by cancer severity to facilitate care decisions and guide the specifics of implementing the selected management options. The summary presented herein represents Part I of the two-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline discussing risk stratification and care options by cancer severity. Please refer to Part II for discussion of specific care options and outcome expectations and management...
December 1, 2017: Journal of Urology
https://www.readbyqxmd.com/read/29202108/kras-biomarker-testing-disparities-in-colorectal-cancer-patients-in-new-mexico
#10
Alissa Greenbaum, Charles Wiggins, Angela Lw Meisner, Manuel Rojo, Anita Y Kinney, Ashwani Rajput
Introduction: American Society of Clinical Oncology (ASCO) guidelines recommend that all patients with metastatic colorectal cancer (mCRC) receive KRAS testing to guide anti-EGFR monoclonal antibody treatment. The aim of this study was to assess for disparities in KRAS testing and mutational status. Methods: The New Mexico Tumor Registry (NMTR), a population-based cancer registry participating in the National Cancer Institute's Surveillance, Epidemiology and End Results program, was queried to identify all incident cases of CRC diagnosed among New Mexico residents from 2010 to 2013...
November 2017: Heliyon
https://www.readbyqxmd.com/read/29198341/concomitant-use-of-corticosteroids-and-immune-checkpoint-inhibitors-in-patients-with-hematologic-or-solid-neoplasms-a-systematic-review
#11
REVIEW
A Garant, C Guilbault, T Ekmekjian, Z Greenwald, P Murgoi, T Vuong
PURPOSE: Clinical trials studying immune checkpoint inhibitors exclude patients on corticosteroids, due to the hypothesis that corticosteroids may antagonize immunotherapy. We performed a systematic review of the literature looking at the clinical outcomes of cancer patients treated with immune checkpoint inhibitors and concomitant corticosteroids. METHODS: The following databases were searched for relevant studies: MEDLINE, Embase Classic+Embase, BIOSIS Previews, the Cochrane Database of Systematic Reviews, the CENTRAL Registry of Controlled Trials, Web of Science and Scopus...
December 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29198325/ercc1-as-a-prognostic-factor-for-survival-in-patients-with-advanced-urothelial-cancer-treated-with-platinum-based-chemotherapy-a-systematic-review-and-meta-analysis
#12
REVIEW
Yuksel Urun, Jeffrey J Leow, Andre P Fay, Laurence Albiges, Toni K Choueiri, Joaquim Bellmunt
BACKGROUND: The predictive role of excision repair cross-complementing group 1 (ERCC1) as a predictive factor in patients with advanced urothelial cancer (AUC) treated with platinum-based treatment is not well defined. Here, we evaluate the role of ERCC1 in patients with AUC treated with platinum-based treatment. METHODS: We performed comprehensive, systematic computerized search to identify relevant studies through Medline, Embase, Cochrane Controlled Trials Register (CCTR) databases and abstracts from American Society of Clinical Oncology (ASCO) and ASCO Genitourinary Cancers Symposium, European Society For Medical Oncology (ESMO) and European Association of Urology (EAU) meeting up to July 2015...
December 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29182495/platelet-transfusion-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update
#13
Charles A Schiffer, Kari Bohlke, Meghan Delaney, Heather Hume, Anthony J Magdalinski, Jeffrey J McCullough, James L Omel, John M Rainey, Paolo Rebulla, Scott D Rowley, Michael B Troner, Kenneth C Anderson
Purpose To provide evidence-based guidance on the use of platelet transfusion in people with cancer. This guideline updates and replaces the previous ASCO platelet transfusion guideline published initially in 2001. Methods ASCO convened an Expert Panel and conducted a systematic review of the medical literature published from September 1, 2014, through October 26, 2016. This review builds on two 2015 systematic reviews that were conducted by the AABB and the International Collaboration for Transfusion Medicine Guidelines...
November 28, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29182492/platelet-transfusion-for-patients-with-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update-summary
#14
Charles A Schiffer, Kari Bohlke, Kenneth C Anderson
No abstract text is available yet for this article.
November 28, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29180872/therapeutic-efficacy-and-safety-of-combined-braf-and-mek-inhibition-in-patients-with-malignant-melanoma-a-meta-analysis
#15
Peng Chen, Fuchao Chen, Benhong Zhou
Background: Recent clinical studies have shown that initial therapy with combined BRAF and mitogen-activated extracellular signal-regulated kinase (MEK) inhibition is more effective in metastatic melanoma than single-agent BRAF inhibitors. However, the response rates with single-agent BRAF are low. Thus, the objective of this study was to conduct a meta-analysis of randomized controlled trials to compare the efficacy and adverse events risk between mono-therapy and combination therapy...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29178132/thrombopoietin-receptor-agonists-for-prevention-and-treatment-of-chemotherapy-induced-thrombocytopenia-in-patients-with-solid-tumours
#16
REVIEW
Xia Zhang, Yunhai Chuai, Wei Nie, Aiming Wang, Guanghai Dai
BACKGROUND: Chemotherapy-induced thrombocytopenia (CIT) is defined as a peripheral platelet count less than 100×109/L, with or without bleeding in cancer patients receiving myelosuppressive chemotherapy. CIT is a significant medical problem during chemotherapy, and it carries the risk of sub-optimal overall survival and bleeding. Alternative interventions to platelet transfusion are limited. Different stages of preclinical and clinical studies have examined the thrombopoietin receptor agonists (TPO-RAs) for CIT in patients with solid tumours...
November 27, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29174780/hospitalization-costs-after-surgery-in-high-risk-patients-with-early-stage-lung-cancer
#17
Manu S Sancheti, Ray K Chihara, Sebastian D Perez, Onkar V Khullar, Felix G Fernandez, Allan Pickens, Seth D Force
BACKGROUND: We previously reported that early stage lung cancer patients who are considered high risk for surgery can undergo resection with favorable perioperative results and long-term mortality. To further elucidate the role of surgical resection in this patient cohort, this study evaluated the length of stay and total hospitalization cost among patients classified as standard or high risk with early stage lung cancer who underwent pulmonary resection. METHODS: A total of 490 patients from our institutional Society of Thoracic Surgeons data from 2009 to 2013 underwent resection for clinical stage I lung cancer...
November 23, 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29174221/lung-toxicity-in-non-small-cell-lung-cancer-patients-exposed-to-alk-inhibitors-report-of-a-peculiar-case-and-systematic-review-of-the-literature
#18
REVIEW
Benedetta Pellegrino, Francesco Facchinetti, Paola Bordi, Mario Silva, Letizia Gnetti, Marcello Tiseo
Lung toxicity is a potential fatal effect involving non-small-cell lung cancer (NSCLC) patients exposed to tyrosine kinase inhibitors (TKIs). Moving from our experience regarding a patient who developed lung toxicity while receiving 2 different anaplastic lymphoma kinase (ALK)-TKIs, we performed a systematic review to assess the epidemiologic magnitude and the clinical significance of such toxicity in NSCLC patients treated with ALK-TKIs. Studies were identified using MEDLINE and additional sources (European Society for Medical Oncology, American Society of Clinical Oncology, and World Conference on Lung Cancer abstracts) in agreement with Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane guidelines...
October 28, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29172913/use-of-larynx-preservation-strategies-in-the-treatment-of-laryngeal-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update-summary
#19
Arlene A Forastiere, Nofisat Ismaila, Gregory T Wolf
No abstract text is available yet for this article.
November 27, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/29172863/use-of-larynx-preservation-strategies-in-the-treatment-of-laryngeal-cancer-american-society-of-clinical-oncology-clinical-practice-guideline-update
#20
Arlene A Forastiere, Nofisat Ismaila, Jan S Lewin, Cherie Ann Nathan, David J Adelstein, Avraham Eisbruch, Gail Fass, Susan G Fisher, Scott A Laurie, Quynh-Thu Le, Bernard O'Malley, William M Mendenhall, Snehal Patel, David G Pfister, Anthony F Provenzano, Randy Weber, Gregory S Weinstein, Gregory T Wolf
Purpose To update the guideline recommendations on the use of larynx-preservation strategies in the treatment of laryngeal cancer. Methods An Expert Panel updated the systematic review of the literature for the period from January 2005 to May 2017. Results The panel confirmed that the use of a larynx-preservation approach for appropriately selected patients does not compromise survival. No larynx-preservation approach offered a survival advantage compared with total laryngectomy and adjuvant therapy as indicated...
November 27, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
77718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"